Journal article
Comparison of Characteristics and Outcomes of Dabigatran Versus Warfarin in Hypertensive Patients With Atrial Fibrillation (from the RE-LY Trial)
Abstract
Hypertension is frequent in patients with atrial fibrillation (AF) and is an independent risk factor for stroke. The Randomized Evaluation of Long Term Anticoagulant TherapY (RE-LY) trial found dabigatran 110 mg (D110) and 150 mg twice daily (D150) noninferior or superior to warfarin for stroke reduction in patients with AF, with either a reduction (D110) or similar rates (D150) of major bleeding. Baseline characteristics and outcomes were …
Authors
Nagarakanti R; Wallentin L; Noack H; Brueckmann M; Reilly P; Clemens A; Connolly SJ; Yusuf S; Ezekowitz MD
Journal
The American Journal of Cardiology, Vol. 116, No. 8, pp. 1204–1209
Publisher
Elsevier
Publication Date
October 2015
DOI
10.1016/j.amjcard.2015.07.032
ISSN
0002-9149